Your browser doesn't support javascript.
loading
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott, David F; Huseni, Mahrukh A; Atkins, Michael B; Motzer, Robert J; Rini, Brian I; Escudier, Bernard; Fong, Lawrence; Joseph, Richard W; Pal, Sumanta K; Reeves, James A; Sznol, Mario; Hainsworth, John; Rathmell, W Kimryn; Stadler, Walter M; Hutson, Thomas; Gore, Martin E; Ravaud, Alain; Bracarda, Sergio; Suárez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni K; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S; Hegde, Priti S; Schiff, Christina; Fine, Gregg D; Powles, Thomas.
Afiliação
  • McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA, USA. dmcdermo@bidmc.harvard.edu.
  • Huseni MA; Genentech, Inc., South San Francisco, CA, USA.
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rini BI; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Escudier B; Gustave Roussy, Villejuif, France.
  • Fong L; University of California, San Francisco School of Medicine, San Francisco, CA, USA.
  • Joseph RW; Mayo Clinic Hospital -Florida, Jacksonville, FL, USA.
  • Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Reeves JA; Florida Cancer Specialists, Fort Myers, FL, USA.
  • Sznol M; Yale School of Medicine, New Haven, CT, USA.
  • Hainsworth J; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Rathmell WK; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Stadler WM; University of Chicago Medicine, Chicago, IL, USA.
  • Hutson T; Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
  • Gore ME; Royal Marsden Hospital, London, UK.
  • Ravaud A; CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France.
  • Bracarda S; Ospedale San Donato, Azienda USL Toscana Sudest, Arezzo, Italy.
  • Suárez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Danielli R; Azienda Ospedaliera Universitaria Senese, Center for Immune-Oncology, Siena, Italy.
  • Gruenwald V; Medizinische Hochschule, Zentrum Innere Medizin, Abt. Hämatologie u. Onkologie, Hannover, Germany.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Nickles D; Genentech, Inc., South San Francisco, CA, USA.
  • Jhunjhunwala S; Genentech, Inc., South San Francisco, CA, USA.
  • Piault-Louis E; Genentech, Inc., South San Francisco, CA, USA.
  • Thobhani A; Roche Products Ltd, Welwyn Garden City, UK.
  • Qiu J; Genentech, Inc., South San Francisco, CA, USA.
  • Chen DS; Genentech, Inc., South San Francisco, CA, USA.
  • Hegde PS; Genentech, Inc., South San Francisco, CA, USA.
  • Schiff C; Genentech, Inc., South San Francisco, CA, USA.
  • Fine GD; Genentech, Inc., South San Francisco, CA, USA.
  • Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.
Nat Med ; 24(12): 1941, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30291359
ABSTRACT
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos